Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT05919069
PHASE1

A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693

Sponsor: AstraZeneca

View on ClinicalTrials.gov

Summary

Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment

Official title: A Single Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of AZD2693.

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

35

Start Date

2023-06-16

Completion Date

2024-09-16

Last Updated

2026-05-11

Healthy Volunteers

Yes

Interventions

DRUG

AZD2693

Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment

Locations (3)

Research Site

Rialto, California, United States

Research Site

Miami Lakes, Florida, United States

Research Site

Orlando, Florida, United States